USS Investment Management Ltd Grows Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

USS Investment Management Ltd raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 19,315 shares of the biopharmaceutical company’s stock after buying an additional 1,035 shares during the quarter. USS Investment Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $14,914,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of REGN. WPG Advisers LLC grew its holdings in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the period. Board of the Pension Protection Fund acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. Entrust Financial LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $32,000. MCF Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 15 shares during the period. Finally, Transamerica Financial Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 380.0% during the fourth quarter. Transamerica Financial Advisors LLC now owns 48 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 38 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director owned 17,503 shares in the company, valued at $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on REGN shares. Royal Bank Of Canada dropped their target price on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating on the stock in a report on Monday, May 18th. Wells Fargo & Company dropped their target price on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a report on Monday, May 18th. Leerink Partners reaffirmed a “market perform” rating and set a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, Canaccord Genuity Group dropped their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $792.65.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $612.14 on Monday. The company has a market capitalization of $64.72 billion, a P/E ratio of 14.92, a P/E/G ratio of 1.34 and a beta of 0.25. The business’s 50 day moving average is $692.11 and its two-hundred day moving average is $738.00. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12-month low of $503.25 and a 12-month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $8.22 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.